Paloma Pharmaceuticals Receives Approval to Enter Phase I Clinical Trials
IND Accepted by FDA to Initiate Intravitreal and Subconjunctival Administration of Palomid 529 in Age-Related Macular Degeneration Patients -
09-Feb-2010 -
Paloma Pharmaceuticals, Inc. announced that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic ...
clinical trials
inhibitors
medicinal chemistry
+3